Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis

The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PM...

Full description

Bibliographic Details
Main Authors:	María García-Fortes, Juan C. Hernández-Boluda, Alberto Álvarez-Larrán, José M. Raya, Anna Angona, Natalia Estrada, Laura Fox, Beatriz Cuevas, María C. García-Hernández, María Teresa Gómez-Casares, Francisca Ferrer-Marín, Silvana Saavedra, Francisco Cervantes, Regina García-Delgado, on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Cancers
Subjects:	myelofibrosis comorbidities survival prognosis
Online Access:	https://www.mdpi.com/2072-6694/14/9/2331

Similar Items

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
by: Rosa Ayala, et al.
Published: (2023-05-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Primary myelofibrosis L.
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping
by: Álvaro Díaz-González, et al.
Published: (2023-06-01)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
by: Barnali Srivastava, et al.
Published: (2023-09-01)

Myelofibrosis: An unusual presentation of disseminated tuberculosis
by: Neha Sharma, et al.
Published: (2020-01-01)

Pediatric immune myelofibrosis (PedIMF) as a novel and distinct clinical pathological entity
by: Fabiola Guerra, et al.
Published: (2022-11-01)

Possibilities of targeted therapy for myelofibrosis: Moscow experience
by: O. Yu. Vinogradova, et al.
Published: (2022-11-01)

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
by: Elisa Rumi, et al.
Published: (2020-11-01)

Idiopathic myelofibrosis mimicking hemolytic anemia
by: R Baral, et al.
Published: (2012-09-01)

Long-term results of splenectomy in primary myelofibrosis
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Long-term results of splenectomy in primary myelofibrosis
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Mutation profile in Indian primary myelofibrosis patients and its clinical implications
by: Vinod R Patil, et al.
Published: (2019-01-01)

Benign Parathyroid Adenoma Presenting with Unusual Parathyroid Crisis, Anemia and Myelofibrosis
by: Shu-Chuan Huang, et al.
Published: (2007-01-01)

SPECTRUM OF AFFECTED GENES IN UKRAINIAN PATIENTS WITH PRIMARY MYELOFIBROSIS
by: Poluben L., et al.
Published: (2018-12-01)

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing
by: Marta Garrote, et al.
Published: (2023-07-01)

Livedoid Pattern in the Abdomen of a Patient with Myelofibrosis: A Quiz
by: Diego Soto-García, et al.
Published: (2022-01-01)

Autoinflammation and Myelofibrosis: Report of a Case
by: Prasad Koduri, et al.
Published: (2023-08-01)

Primary autoimmune myelofibrosis: A case report in a child
by: Zufit Hexner‐Erlichman, et al.
Published: (2020-07-01)

Trends in overall mortality among US veterans with primary myelofibrosis
by: Tsewang Tashi, et al.
Published: (2023-01-01)

Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01)

Patients with primary myelofibrosis: treatment and quality of life
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

Patients with primary myelofibrosis: treatment and quality of life
by: L. M. Meshcheryakova, et al.
Published: (2014-07-01)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
by: Francesca Palandri, et al.
Published: (2023-10-01)

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
by: Tanvi Verma, et al.
Published: (2024-01-01)

Disseminated tuberculosis with myelofibrosis presentation: a case report
by: Mahdi Khatuni, et al.
Published: (2021-11-01)

Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient
by: Tuğçe Bulakbaşı Balcı, et al.
Published: (2010-06-01)

Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient
by: Tuğçe Bulakbaşı Balcı, et al.
Published: (2010-06-01)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
by: Bruno Deltreggia Benites, et al.
Published: (2013-01-01)

Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01)

Urticarial vasculitis coexisting with primary myelofibrosis – a case report
by: Radomir Reszke, et al.
Published: (2017-12-01)

IMPACT OF THE IMPAIRED IRON HOMEOSTASIS ON THE PATHOGENESIS OF ANEMIA IN PRIMARY MYELOFIBROSIS
by: Liana Gercheva, et al.
Published: (2016-03-01)

Standard care and investigational drugs in the treatment of myelofibrosis
by: Daniela Barraco, et al.
Published: (2019-09-01)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
by: Giacomo Coltro, et al.
Published: (2023-04-01)

Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the national center of hematology
by: Alaa F. Alwan
Published: (2015-01-01)

Primary autoimmune myelofibrosis: a report of three cases and review of the literature
by: Rakhee Kar, et al.
Published: (2009-09-01)

New Markers of Disease Progression in Myelofibrosis
by: Rita Campanelli, et al.
Published: (2021-10-01)

Acute massive myelofibrosis with acutelymphoblastic leukemia
by: Namık Özbek, et al.
Published: (2009-12-01)

Primary myelofibrosis: current therapeutic options
by: Paula de Melo Campos

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
by: Adrin Dadkhah, et al.
Published: (2022-05-01)